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TF and TFPI in myeloproliferative 
neoplasms — a preliminary study
ABSTRACT
Introduction. Haemostatic disturbances such as thrombosis or diathesis are frequent complications in 
patients with myeloproliferative neoplasms (MPNs). The purpose of this study was to evaluate the con-
centration of tissue factor (TF), tissue factor pathway inhibitor (TFPI), and thrombin–antithrombin (TAT) 
complexes in patients with MPNs.
Patients and methods. The study involved 43 patients with MPNs (mean age 60.5 years), including 
16 patients with essential thrombocythaemia, eight with polycythaemia vera, ten with chronic myeloid 
leukaemia, and nine with primary myelofibrosis. The control group consisted of 30 healthy volunteers 
who were age- and sex-matched. TF, TFPI and TAT complexes concentration were measured using the 
immunoenzyme method.
Results. TF and TAT complex concentrations were significantly higher, but the TFPI concentration was 
lower, in the total study group compared to the control group. TF concentration in each of the subgroups 
was significantly higher than in the control group. TFPI concentration was significantly lower in essential 
thrombocythaemia and polycythaemia vera than in controls. In addition, the concentration of TAT complex 
in patients with chronic myeloid leukaemia was significantly higher than in the control group.
Conclusions. Elevated TF levels and decreased TFPI levels in patients with essential thrombocythaemia 
and polycythaemia vera indicate the activation of blood coagulation process depending on the TF 
(an extrinsic pathway). These patients represent a group at high risk of thrombotic complications.
Key words: myeloproliferative neoplasms, thrombin–antithrombin complexes, tissue factor, tissue factor 
pathway inhibitor, thrombotic complications
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Introduction
Myeloproliferative neoplasms (MPNs) are the 
result of clonal proliferation of stem cells of bone 
marrow, characterised by the proliferation of one or 
more myeloid lines (granulocyte, erythrocyte, and 
megakaryocyte) of the bone marrow [1]. The diverse 
clinical manifestations of various myeloproliferative 
neoplasms appear to be the result of the clonal cells 
acquiring additional molecular abnormalities that lead 
to disturbances in the signal transduction pathways of 
cell proliferation signals and the signals initiating and 
sustaining the cell maturation. The first cancer to have 
been associated with the development of specific cy-
togenetic changes, the translocation of the fragments 
of the long arms between chromosomes 9 and 22, 
resulting in the emergence of fusion gene BCR-ABL on 
the Ph chromosome, was chronic myeloid leukaemia.
In 2008, the World Health Organisation (WHO) 
changed the previously applicable classification of 
chronic myeloproliferative diseases (CMPDs). The 
reason for the changes in this classification was to 
investigate the molecular causes of myeloproliferative 
neoplasms, the beginning of which was the 2005 dis-
covery of the relationship between gene mutation V617F 
Janus tyrosine kinase 2 (JAK-2) and polycythaemia 
vera and the 2006 discovery of two other somatic mu-
tations: W515L and W515K within the gene sequence 
for thrombopoietin (MPL) [2]. It was the discovery of 
fusion genes with the participation of PDGFRA and 
PDGFRB genes located on chromosome 4q12 and 
5q33, respectively, which was of great importance in 
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developing the understanding of the pathogenesis of 
myeloproliferative neoplasms. The creation of these 
genes, e.g. FIP1L1-PDGFRA or PDGFRB, leads to 
the activation of oncogenic tyrosine kinases and the 
occurrence of myeloproliferative neoplasms with eo-
sinophilia [3]. 
In the new classification, the term ‘chronic my-
eloproliferative syndromes’ has been replaced by 
‘myeloproliferative neoplasms’, which better reflects 
the clinical pattern and course of the diseases. The new 
WHO classification covers the following myeloprolifer-
ative neoplasms: chronic myeloid leukaemia (CML), 
polycythaemia vera (PV), essential thrombocythaemia 
(ET), primary myelofibrosis (PMF), mastocytosis (SM), 
chronic eosinophilic leukaemia (CEL), unclassified 
differently chronic neutrophilic leukaemia (CNL), and 
unclassified MPNs [4, 5].
The changes proposed by the WHO are due to the 
discovery of gene mutations that result in the overpro-
duction of proteins with the properties of tyrosine kinas-
es that are responsible for the proliferation of various 
cell lines. The presence of the fusion gene BCR / ABL, 
KIT gene mutations, fusion gene FIP1L1/PDGFRA and 
JAK2 gene mutations indicates the oncogenic origin of 
myeloproliferative neoplasms [6]. The JAK2 mutation 
has been confirmed in more than 90% of patients with 
polycythaemia vera and in 50% of patients with primary 
myelofibrosis and essential thrombocythaemia [7]. The 
detection of mutations in JAK2 gene or MPL excludes 
a diagnosis of reactive erythrocytosis, thrombocytosis, 
or bone marrow fibrosis. However, it does not determine 
the differential diagnosis between the types of myelop-
roliferative neoplasms [8].
It is well known that in patients with MPNs a frequent 
complication and clinical problem at the same time are 
haemostatic disturbances: thrombosis or diathesis. The 
mechanisms of bleeding and thrombotic complications 
in those patients are complex and can be the result of: 
morphological or functional platelets abnormalities, 
blood hyperviscosity state, the interactions between 
blood morphology components (an increase in the 
adhesion of platelet-leukocyte complexes, mono-
cytes-platelets), the disorders of coagulation factors and 
some inhibitors, fibrinolytic system disorders as well as 
endothelial dysfunction disorders [9–11].
Currently, it is believed that the activation of the 
extrinsic coagulation process dependent on the 
tissue factor (TF) plays a key role in the initiation of 
blood coagulation. The activation of this pathway 
starts from the generation of tissue factor (TF), which 
is a cell membrane glycoprotein with the molecular 
weight of 47kDa acting as cofactor for factor VII. 
Having activated factor VII, TF forms a complex with 
factor VIIa, and then activates factors IX and X, which, 
in turn, leads to the formation of fibrin fibres [12]. 
Recent studies have indicated that the tissue factor 
can be a link between haemostasis, angiogenesis 
and inflammation [13, 14].
The main tissue factor-dependent coagulation reg-
ulator is the tissue factor pathway inhibitor (TFPI). TFPI 
is a protein consisting of 276 aminoacids. TFPI inacti-
vates the complex of TF/FVIIa and active factor X (FXa). 
TFPI is mainly synthesised by endothelial cells and so 
is responsible for maintaining the endothelium antico-
agulant potential [15, 16].
Information regarding coagulation disorders in 
the course of myeloproliferative neoplasms is scarce. 
Thus the purpose of this study was to evaluate the con-
centration of TF, TFPI and TAT complexes in patients 
with MPNs.
Materials and methods
The study involved 43 patients with myeloprolifer-
ative neoplasms aged 21–86 years (mean age 60.53), 
hospitalised and diagnosed at the Clinical Ward of 
Haematology of the Dr. J. Biziel University Hospital No. 
2 in Bydgoszcz. These patients were enrolled in the 
study at the time of the diagnosis of MPNs and prior to 
the implementation of appropriate treatment. Patients 
without clinically overt thrombosis were included in the 
study. The study group consisted of 16 patients with ET, 
eight with PV, ten with CML, and nine with PMF. The 
diagnosis of essential thrombocythaemia was based 
on the diagnostic criteria of essential thrombocythae-
mia according to the WHO (2008) and the exclusion 
of other malignant and non-malignant diseases in 
the course of which there can be observed essential 
thrombocythaemia. The diagnosis of polycythaemia 
vera was based on the diagnostic criteria for poly-
cythaemia vera according to the WHO (2008), including 
a genetic test for the JAK2 V617F gene mutation. In all 
patients with polycythaemia vera, there were initially 
excluded secondary causes of polycythaemia vera: 
hypoxia induced in the course of pulmonary and heart 
diseases or other causes due to increased production 
of EPO independent of tissue hypoxia, and there were 
excluded the causes of alleged polycythaemia. In these 
patients the erythropoietin level in serum was not de-
termined. The diagnosis of chronic myeloid leukaemia 
was based on: the clinical picture, the study results, 
including additional cytogenetic and molecular studies, 
which demonstrated the presence of the translocation 
t(9;22) (q34;q11) and the presence of gene BCR/ABL 
in RQ-PCR testing. Myelofibrosis diagnosis was based 
on the diagnostic criteria for spontaneous bone marrow 
fibrosis, according to the WHO (2008), including the 
study on the presence of cytogenetic V617F mutation 
in JAK2 gene.
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Table 1. Concentration of TF, TFPI and TAT complexes in the study group compared to the control group
Parameter Study group n = 43 Control group n = 30  Significance 
 level (p)Me Min–Max Q1; Q3 Me Min–Max Q1; Q3
TF [pg/mL] 334.43 123.82–6,315.64 250.52; 836.44 164.28 90.44–355.13 117.39; 183.85  < 0.00001
TFPI [ng/mL] 54.48 26.24–375.80 41.64; 82.64 83.533 52.22–137.92 68.96; 94.78  0.000263
TAT [ng/mL] 6.09 0.02–176.96 1.72; 14.20 2.49 0.73–10.60 1.44; 3.92  0.038394
TF — tissue factor; TFPI — tissue factor pathway inhibitor; TAT — thrombin–antithrombin complexes
The control group consisted of 30 healthy volun-
teers, age- and gender-matched. 
Venous blood was collected from the elbow vein into 
tubes containing 3.2% sodium citrate (anticoagulant/blood 
ratio 1:9). The basic parameters of coagulation, such as 
activated partial thromboplastin time (APTT), prothrombin 
time (PT), concentrations of fibrinogen and D-dimer, were 
assayed using a BCS XP coagulation analyser (Siemens). 
In plasma the following tests were performed using the 
ELISA method: the concentration of TF (Imubind Tissue 
Factor ELISA kit, American Diagnostica Inc.), the concen-
tration of TFPI (Imubind Total TFPI ELISA kit, American 
Diagnostica Inc.), and TAT complexes concentration 
(Imubind TAT ELISA kit, American Diagnostica Inc.).
Statistical analysis was performed using Statistica 
9.1 software (StatStoft®). The Shapiro-Wilk test was 
used to assess the normality of the distribution. For the 
parameters with a normal distribution, arithmetic mean 
(X) and standard deviations (SD) were determined, 
and the parameters with abnormal distribution were 
presented as medians (Me) and quartiles: lower (Q1) 
and upper (Q3). The Mann Whitney U test was used to 
compare the differences between groups. Spearman 
correlation coefficients were calculated to determine 
if there were any correlations between the parame-
ters. The p-values < 0.05 were considered significant.
The study was approved by the Bioethics Commit-
tee of Collegium Medicum in Bydgoszcz, the Nicolaus 
Copernicus University in Torun (no. KB/396/2010). 
Results
The tissue factor and the TAT complex concentration 
were significantly higher in patients with myelopro-
liferative neoplasms compared to the control group. 
However, the concentration of tissue factor pathway 
inhibitor was significantly lower in the total study group 
compared to the control group (Tab. 1).
Tables 2 and 3 show a detailed analysis of the 
results recorded in respective subgroups of patients 
with myeloproliferative neoplasms compared to the 
control group.
The results of the basic parameters of haemostasis 
(APTT, PT) in all subgroups were different from the 
values reported in the control group, although these 
results fell within the reference ranges. The concen-
tration of fibrinogen in the subgroups with essential 
thrombocythaemia, chronic myeloid leukaemia and 
myelofibrosis were significantly higher than in the 
control group. These results also fell within the normal 
range. The D-dimer concentration was significantly 
higher in the subgroups with CML and PMF compared 
to the control group.
Moreover, it was observed that the TF concentration 
in each of the subgroups: essential thrombocythaemia, 
polycythaemia vera, myelofibrosis and chronic myeloid 
leukaemia was significantly higher than in the control 
group. The TFPI concentration was lower in each of the 
subgroups analysed compared to the control group, 
although the difference was significant only for essential 
thrombocythaemia and polycythaemia vera. In addition, 
analysing the concentration of TAT complex in patients 
with MPNs, it was observed that only for patients with 
chronic myeloid leukaemia was the concentration of this 
parameter significantly higher than in the control group.
The genetic studies analysis showed that out of eight 
patients with PV, seven revealed the presence of V617F 
JAK-2 mutation, while the other one did not show such 
a mutation. Among the ET respondents, JAK-2 mutation 
occurred in 11 and did not occur in five.
In view of the hypothesis by Rak et al., assuming 
that TF is a molecular link between genetic determinant 
of tumour progression and cancer coagulopathy, we 
performed a statistical analysis to evaluate the con-
centrations of the parameters tested in ET patients to 
identify the presence of the JAK-2 gene mutations [13]. 
We found no significant differences in the subgroups 
of patients with essential thrombocythaemia, although 
the median TF levels differed, and it was clearly higher 
in the patients with JAK-2 mutation (Tab. 4). The study 
needs to be continued on a greater number of patients. 
Discussion
Haemostatic disorders in the form of thrombo-
embolic complications, bleeding complications, and 
disseminated intravascular coagulation syndrome are 
among frequent abnormalities in cancer patients. These 
complications are the second cause of death in patients 
diagnosed with cancer [17, 18].
34
folia Medica copernicana 2014, vol. 2, no. 1
www.fmc.viamedica.pl
Table 2. Comparison of the concentration of haemostatic parameters in various subgroups of patients with MPNs, 
and in relation to the control group
Parameter ET  
n = 16 (I)
PV  
n = 8 (II)
CML  
n = 10 (III)
PMF  
n = 9 (IV)
Control group  
n = 30 (C)
Significance 
level (p)
M/Me ± SD/ 
/(Q1; Q3)
M/Me ± SD/ 
/(Q1; Q3)
M/Me ± SD/ 
/(Q1; Q3)
M/Me ± SD/ 
/(Q1; Q3)
M/Me ± SD/ 
/(Q1; Q3) 
APTT [s] 36.10  
(33.80; 39.60)
39.50  
(33.40; 46.30)
34.05  
(29.05; 38.10)
33.70  
(29.80; 36.60)
30.00  
(27.90; 32.80)
I vs. C  
p = 0.000031 
II vs. C  
p = 0.000987 
III vs. C  
p = 0.080267 
IV vs. C  
p = 0.098944
PT [s] 12.70 ± 0.90 13.20 ± 0.70 13.25 ± 0.50 12.80 ± 0.80 12.30 ± 0.90 I vs. C  
p = 0.119526 
II vs. C  
p = 0.067837 
III vs. C  
p = 0.050884 
IV vs. C  
p = 0.170166
Fibrinogen  
[g/dL]
3.10  
(2.60; 3.70)
2.50  
(2.00; 2.90)
3.3  
(2.90; 3.60)
4.60  
(3.65; 5.45)
2.60  
(2.00; 3.00)
I vs. C  
p = 0.028844 
II vs. C  
p = 0.969067 
III vs. C  
p = 0.001456 
IV vs. C  
p = 0.000170
D-dimer  
[ng/mL]
340.00  
(245.00; 414.00)
293.50  
(225.00; 1,243.00)
616,00  
(457.00; 1,167.00)
881,00  
(417.00; 1,814.00)
242.00  
(188.00; 312.00)
I vs. C  
p = 0.050842 
II vs. C  
p = 0.274801 
III vs. C  
p = 0.000030 
IV vs. C  
p = 0.000437
ET — essential thrombocythaemia; PV— polycythaemia vera; CML — chronic myelogenous leukaemia; PMF — primary myelofibrosis; APTT  
— activated partial thromboplastin time; INR — international normalised ratio; PT — prothrombin time
In our study, patients diagnosed with myeloprolifer-
ative neoplasms demonstrated significantly higher TF 
levels in the total study group compared to the control 
group. A detailed analysis of the results reported in 
different subgroups of patients with MPNs, compared 
to the control group, showed that the TF concentration 
in each of the subgroups: essential thrombocythaemia, 
polycythaemia vera, myelofibrosis, and chronic myeloid 
leukaemia was significantly higher than in the control 
group. 
The coagulation activation is initiated by the extrinsic 
pathway, the key element of which is the tissue factor (TF). 
The TF is found on the surface of many cells (e.g. sub-
endothelial layer and adventitia vessels); it is a cellular 
receptor of plasma factor VII. In the place of the vessel 
wall damage, the tissue factor comes into contact with 
factor VII and complex TF/VIIa is formed, which gives 
rise to the processes leading to the production of throm-
bin and, consequently, the fibrin clot [19].
The findings of other studies show that the presence 
of the tissue factor in tumour cells is of highly predictive 
and prognostic value [20, 21]. A positive correlation has 
been found between the TF expression in tumour cells 
and the frequency of the incidence of metastasis and 
progression of the disease, e.g. in patients diagnosed 
with colorectal cancer, breast cancer, and non-small cell 
lung cancer [21–23]. A correlation was also observed 
between the increase in the occurrence of thrombotic 
events in cancer patients and significantly higher levels 
of tissue factor expression [21]. Uno et al. observed an 
increased TF expression in patients with ovarian cancer, 
which was positively correlated with the development 
of venous thromboembolism in those patients [23].
An analysis of the available literature showed that 
there are few reports on the role of the tissue factor 
in patients with myeloproliferative neoplasms. In-
creased TF levels in patients with acute myeloid leu-
kaemia have been reported, which, according to the 
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Table 3. Comparison of the concentration of TF and TFPI and TAT complexes in various subgroups of patients with 
MPNs, and in relation to the control group
Parameter ET 
n = 16 (I)
PV 
n = 8 (II)
CML 
n = 10 (III)
PMF 
n = 9 (IV)
Control group  
n = 30 (C)
Significance 
level (p)
Me 
Q1; Q3
Me 
Q1; Q3
Me 
Q1; Q3
Me 
Q1; Q3
Me 
Q1; Q3
TF 
[pg/ml]
378.36 
257.32; 964.67
319.70 
211.14; 705.04
463.78 
306.32; 666.56
334.43 
195.94; 530.32
130.13 
106.83; 170.19
I vs. C 
p = 0.000001 
II vs. C 
p = 0.00024 
III vs. C 
p = 0.000046 
IV vs. C 
p = 0.004372
TFPI  
[ng/ml]
47.98 
42.30; 71.18
41.98 
37.22; 60.70
74.26 
47.44; 105.20
63.84 
55.04; 102.64
72.50 
53.76; 98.72
I vs. C 
p = 0.01082 
II vs. C 
p = 0.03029 
III vs. C 
p = 0,254259 
IV vs. C 
p = 
0.166564
TAT  
[ng/ml]
2.74 
1.66; 11.26
6.09 
0.51; 9.50
19.14 
5.24; 19.76
2.84 
0.28; 27.50
2.24 
1.67; 3.40
I vs. C 
p = 0.11758 
II vs. C 
p = 0.40015 
III vs. C 
p = 0.013329 
IV vs. C 
p = 0.925162
ET — essential thrombocythaemia; PV — polycythaemia vera; CML — chronic myelogenous leukaemia; PMF — primary myelofibrosis; TF — tissue 
factor; TFPI — tissue factor pathway inhibitor; TAT – thrombin–antithrombin complexes
Table 4. TF, TFPI and TAT complexes in the subgroups of patients with essential thrombocythemia JAK-2(+) V617F 
and JAK-2 V617F(–)
Parameter JAK-2 V617F (+) N=11 JAK-2 V617F (–) N=5 p
Me Min.–Max. Q1; Q3 Me Min.–Max. Q1; Q3
TF [pg/mL] 378.36 209.76–1417.24 269.52; 957.88 258.68 217.92–971.46 223.36; 823.04 NS
TFPI [ng/mL] 48.76 28.45–115.36 41.64; 77.56 43.52 33.48–87.80 42.96; 64.80 NS
TAT [ng/mL] 2.74 0.62–176.96 1.66; 11.26 7.40 1.60–14.36 1.78; 14.04 NS
JAK-2 — Janus tyrosine kinase 2; TAT — thrombin–antithrombin complexes; TF — tissue factor; TFPI — tissue factor pathway inhibitor; V617F  
— gene mutation V617F
authors, could suggest an increased procoagulant 
activity [24]. Recent studies have indicated a rela-
tionship between elevated tissue factor levels and the 
presence of JAK2 mutation in cancer patients with 
myeloproliferative neoplasms and an increased 
tendency to thrombosis in these patients [25, 26]. 
In the present study, the analysis of the TF, TFPI and 
TAT concentration, due to JAK-2 mutation or its lack, 
was carried out in ET patients. We found no significant 
difference in the concentrations of the analysed param-
eters in the group of patients with JAK-2 mutation and 
without any such mutation, even though the median TF 
in the patients with JAK-2 gene mutations was higher 
than in the control group. It is possible that an assess-
ment of concentrations in a larger group of patients 
would identify the significance of the differences.
The thrombin generation process is controlled at 
different stages of the coagulation cascade. In this pro-
cess, natural blood coagulation inhibitors are involved, 
including the tissue factor pathway inhibitor (TFPI) [27].
Based on the results reported in this study, we have 
shown significantly lower TFPI concentration in the total 
study group compared to the control group. The TFPI 
levels were lower in each of the subgroups analysed 
compared to the control group. However, only for essen-
tial thrombocythaemia and polycythaemia vera was the 
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difference significant. The lack of significant differences in 
patients with chronic myeloid leukaemia and myelofibro-
sis could be due to the small group of patients involved.
A low concentration and a decreased TFPI activity 
has been observed in patients with acute myeloid leu-
kaemia complicated by disseminated intravascular 
coagulation (DIC). According to the authors, a low TFPI 
concentration could be responsible for the occurrence 
of thrombotic events in these patients [28]. Different 
results were reported by Radziwon et al. who found 
significantly elevated TFPI levels, although the TFPI 
activity was decreased in the course of chronic myeloid 
leukaemia [29].
Our results, and the literature data, suggest that low 
TFPI levels accompanied by high TF concentrations can 
be a predisposing factor to the occurrence of thrombotic 
events in patients with cancer.
Additionally, in this study it was observed that the 
TAT complex concentration was significantly higher in 
the total study group compared to the controls. A de-
tailed analysis showed that only in patients with CML 
was the TAT complex concentration significantly higher 
compared to the control group. A high TAT complex 
concentration can indicate an excessive thrombin 
generation process. Our findings are consistent with 
the previous report by Rość et al. who also observed 
a significantly higher TAT complex concentration in 
chronic myeloid leukaemia [11]. An elevated TAT has 
also been reported in patients with stomach, colon, 
kidney, and prostate cancer [11, 30].
In conclusion, in myeloproliferative neoplasms, 
despite the lack of clinical symptoms of haemostatic 
disorders, the so called ‘thrombophlebitis emergency’ 
occurs, expressed by increased TF and TAT complex 
levels. Low TFPI levels are an additional factor that 
enhances the prothrombotic threat.
Conclusions
The elevated TF levels and decreased TFPI lev-
els in patients with essential thrombocythaemia and 
polycythaemia vera indicate the activation of blood 
coagulation depending on the TF (an extrinsic path-
way). These patients represent a high-risk group of 
thrombotic complications.
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